Almac Launches SupplyTraQ™ Technology Solution to Streamline Clinical Trial Supply Administration
September 23, 2013
Online Tool Enables More Cost-efficient and Accurate Reconciliation and Reporting
Souderton, PA —Almac today announced the launch of SupplyTraQ™, a web-based drug accountability and reconciliation tool that improves clinical trial drug supply management and simplifies post-trial administration. Compatible with IXRS®, the company’s industry-leading IVR/IWR technology, SupplyTraQ enables users to capture drug supply data in real-time and improve the accuracy of the supply management process.
SupplyTraQ accommodates multiple protocols and study designs, offering users a cost-effective method of supporting clinical trials and consolidating trial supply records. Built-in validation checks flag discrepancies as soon as they occur, enabling more accurate data collection and reporting at trial sites and distribution depots.
“SupplyTraQ simplifies the drug accountability, reconciliation, and destruction process – all essential components of clinical trial management,” says Charlie Morris, Vice President, New Products & Services. “By having a real-time view of drug returns, transfers and destruction at both the site and depot levels for discrete drugs, trial managers can take better control of their drug supply and produce higher-quality data.”
SupplyTraQ provides a lower-cost alternative to the manual drug supply management processes used by many clinical trial professionals. Alerts and user-defined search capabilities support fast identification – and resolution – of discrepancies and help to accelerate accountability, reconciliation, and destruction activities. SupplyTraQ further streamlines the process by facilitating authorized, remote review of inventories, enabling site monitors to more efficiently manage their time and site visit schedule. The tool is also adaptable to company-specific processes and trial requirements, which can vary widely depending on study complexity and scope. When used in conjunction with Almac’s IXRS technology, supply management and patient events are completely integrated and yield a holistic view of the drug kit lifecycle.
‘Partnering to Advance Human Health’
Almac’s Clinical Technologies business unit specializes in interactive technology and service solutions to increase the quality and efficiency of clinical trials. Our solutions include Interactive Voice and Web Response Systems (IXRS®) for patient randomization and drug assignment, patient and clinical supplies management, electronic-patient-reported-outcomes data collection, and Web drug reconciliation. Almac’s technologies have been deployed in over 1900 clinical trials, incorporating over 1.8 million patients in over 80 countries and in more than 60 languages.
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately-owned organisation that has organically grown over 30 years and now employs in excess of 3,300 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland, with US operations based in Pennsylvania, North Carolina and California.